Bayer launches SafeTrack, a new digital adverse event reporting channel for the public.
- SafeTrack is an easy, quick and convenient online platform that allows public to report adverse events related with Bayer’s medicines.
- At Bayer, patient safety is the number one priority and we are committed to ensuring the safety of our current and future patients and consumers.
Jakarta, 5 November 2019
Bayer launches SafeTrack (www.safetrack-public.bayer.com) - a easy, quick and convenient adverse event reporting tool for the public globally including Indonesia related with Bayer medicines. Through SafeTrack, the public including Patients and Doctors will be able to easly, quickly and convenient report any adverse events that has occurred to them or their family or friends related with Bayer medicines.
As a leading pharmaceutical company, patient safety is one of Bayer’s core values, and the launch of SafeTrack demonstrates Bayer’s commitment to ensuring the safety of current and future patients and consumers.
President Director Bayer Indonesia, Angel Michael Evangelista says,” At Bayer, patient safety and well-being are our highest priority. We take great pride in always putting our patients first. It is the essence of our business and it is more than just an obligation. It is our commitment to deliver high quality prescription and non-prescription medicines.”
“We are committed to improving the patient experience through the safe and appropriate use of our medicines. Therefore, our Pharmacovigilance colleagues work diligently at every stage of the product lifecycle to ensure that the benefits of our products outweigh the risks,” he added.
Pharmacovigilance colleagues work to detect patterns of side effects, initiate action and collect necessary information to analyze and understand them. Once assessed, measures are developed to prevent, or at least minimize, them in the future. One of the key steps in ensuring the early detection of safety signals is through the reporting of adverse events.
Throughout the years, Bayer has developed an array of tools and platforms for patient safety – work is currently being undertaken to implement an artificial intelligence- based solution to augment drug safety data management. The aim is to increase efficiency to tackle the growing volume of received adverse event reports. The system helps to extract necessary data and classify it accordingly, improving patient safety through the identification of adverse drug reactions.
Bayer is committed to comply with drug safety monitoring and reporting, including in Indonesia. For its commitment and efforts, Bayer Indonesia received the Pharmacovigilance Award from the Indonesia Food and Drug Administration (Badan POM) in 2018.
- END –
SafeTrack: www.safetrack-public.bayer.com or scan the barcode:
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to benefit people by supporting efforts to overcome the major challenges presented by a growing and aging global population. At the same time, the Group aims to increase its earning power and create value through innovation and growth. Bayer is committed to the principles of sustainable development, and the Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2018, the Group employed around 117,000 people and had sales of 39.6 billion euros. Capital expenditures amounted to 2.6 billion euros, R&D expenses to 5.2 billion euros. For more information, go to: www.bayer.com atau www.bayer.co.id.
Kontak untuk Media:
Head of Communications, Public Affairs & Sustainability
Sri Libri Kusnianti
Communications, Public Affairs & Sustainability
Telepon: +62 21 30491320